The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...
“If successful in harnessing DNA instructions and a proprietary delivery platform to reprogram the immune system, Adimune has the potential to lead a new era of addressing diseases through programming ...
In the intricate regulation of inflammation, metabolic reprogramming and posttranslational modification (PTM) have emerged as pivotal players, offering new avenues for understanding the fine-tuned ...
Digestive tract tumors are malignant diseases characterized by high aggressiveness, heterogeneity and metabolic abnormalities. Heterogeneity and drug resistance among tumors pose a serious challenge ...
Opinion
The Well News on MSNOpinion
Rewriting the aging code: How AI is accelerating clinical rejuvenation
For decades, the idea of resetting the biological clock sounded more like speculative fiction than clinical strategy. The discovery of Yamanaka factors by Nobel laureate Shinya Yamanaka, which can ...
Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results